Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
The incidence of prostate cancer in the structure of malignant neoplasms occupies the fourth place, it is 7.3%. 1 414 259 new cases and 375 304 deaths were estimated worldwide in 2020. In recent decades, there was a significant increase in the number of cases of metastatic castration-resistant prost...
Guardado en:
Autor principal: | Nikolai A. Ognerubov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abb954db39ae424695df7310983fff12 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Sumanta Kumar Pal, et al.
Publicado: (2010) -
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Josephina P. M. Vrouwe, et al.
Publicado: (2021) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Benedikt Hoeh, et al.
Publicado: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016)